Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
← catalyst calendarSponsored by Evolus, Inc. (industry) · EOLS — their whole pipeline →. With Avania.
Phase
—
Status
Completed
Study type
Observational
Enrollment
756actual
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-15 | actual | When the study began enrolling |
| Primary completion | 2026-04-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-13 | actual | The whole study's end, after follow-up |
| First posted | 2022-08-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glabellar Frown Lines
Intervention
- Drug: prabotulinumtoxinA — also filed as Jeuveau, Nuceiva
Primary outcome
what the primary-completion date above is the date OFTreatment Emergent Adverse Events
measured From the time of first dose until participant exits the study at 18 months post initial treatment
Permalink · EOLS's whole pipeline · Catalyst calendar · Every registered study · What changed